Copyright
©The Author(s) 2017.
World J Hepatol. Aug 18, 2017; 9(23): 990-1000
Published online Aug 18, 2017. doi: 10.4254/wjh.v9.i23.990
Published online Aug 18, 2017. doi: 10.4254/wjh.v9.i23.990
Table 3 Recommendation for everolimus use in liver transplantation recipients
Indication and regimen | Renoprotective benefit |
EVR in combination with CNI to allow CNI dose reduction | |
Management of CNI neurotoxicity | |
EVR allows temporary withdrawal of CNI till resolution of neurotoxicity | |
Patients | LT recipients with renal function > 60 mL/min |
LT recipients proteinuria < 1 g/24 h | |
Timing | De novo therapy: Initiate EVR at 1 mo from transplant |
Maintenance therapy: Introduce EVR within 1 yr from transplant | |
CNI neurotoxicity: Stop CNI and initiate EVR immediately |
- Citation: Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol 2017; 9(23): 990-1000
- URL: https://www.wjgnet.com/1948-5182/full/v9/i23/990.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i23.990